Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
Regulated Information - Denominator
Atlas Special Opportunities, LLChas converted 12convertible bonds in Oxurion resulting in a EUR 300,000capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.
Leuven, BELGIUM,Boston, MA, US–May 12, 2023– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of (i) 44,669,446 new ordinary shares on May 9, 2023, for a total amount of EUR 200,000, as the result of the conversion of 8 convertible bonds, and (ii) 23,801,967 new ordinary shares on May 12, 2023, for a total amount of EUR 100,000, as the result of the conversion of 4 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 824,233,449 outstanding ordinary shares carrying voting rights (compared to 755,762,036 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
| 79,256,161 |
| 824,233,449 |
| 824,233,449 |
| |
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com Michaël Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com | US Conway Communications Mary T. Conway mtconway@conwaycommsir.com ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 chris.brinzey@westwicke.com |
1Press release Oxurion, 02/03/2023
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Wereldhave announces reappointment of Supervisory Board member Hein Brand at Annual General Meeting of Shareholders24.4.2024 15:31:42 CEST | Press release
Wereldhave is pleased to announce the reappointment of Mr. Hein Brand as member of the Supervisory Board, as approved by the Annual General Meeting of shareholders (AGM) of Wereldhave N.V. In his role as Vice President of the Supervisory Board and Chairman of the Audit Committee, Mr Brand will continue to provide valuable leadership and guidance to the company for a period of two years, ending at the Annual General Meeting in April 2026. Full voting results of the Annual General Meeting will be published on the Company website. Attachment PB CORP 24-04-2024 - Wereldhave AGM reappoints Mr Hein Brand as Supervisory Board member
Leadership Evolution: Zafin Announces Strategic CEO Transition to Propel Future Growth24.4.2024 15:15:00 CEST | Press release
Al Karim Somji to Transition Leadership to Charbel Safadi as Part of Zafin's Long-Term Success Strategy VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Zafin, the leading provider of SaaS core modernization and transformation solutions for banks, today announced a strategic leadership transition that has been part of the company’s long-term success plan. After more than two decades of exemplary leadership, Al Karim Somji will step down as Chief Executive Officer of Zafin. He will continue to serve as an ongoing member of the Board of Directors. As a founder of the Company, Al Karim has been pivotal in shaping Zafin's success, leaving a lasting legacy of excellence and innovation. Under his stewardship, Zafin has experienced significant growth and success, reinforcing its status as a leader in global banking technology. As an active board member and substantial owner, Al Karim will provide essential insight and guidance to ensure a smooth leadership transition. His exten
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership24.4.2024 15:00:00 CEST | Press release
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo. Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cy
FloQast Appoints Josh Glover as President and Chief Revenue Officer24.4.2024 15:00:00 CEST | Press release
Glover brings seasoned leadership to drive company momentum, oversee revenue growth, and market expansion LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- FloQast, a Finance and Accounting Operations Platform provider, today announced the appointment of Josh Glover as President and Chief Revenue Officer (CRO). Glover brings to FloQast an extensive background in leadership in both civilian and military roles and will be instrumental in driving FloQast’s current momentum both in terms of revenue growth, market expansion, and the development of new solutions to better the lives of accounting and finance professionals. Glover will oversee all go-to-market teams (sales, marketing, business development, and customer success) and will report to FloQast co-founder and CEO Mike Whitmire. As part of the transition, former CRO Ken Sims will assume the title of Chief Business Development Officer, a newly created role dedicated to driving growth for FloQast in both new and existing markets. Prior to
Blue Mountain Appoints Global Head of Marketing to Bolster Growth and Secure its Position as the EAM Industry Standard in the Life Sciences Sector24.4.2024 15:00:00 CEST | Press release
Veteran marketing leader to drive global awareness and adoption of their out-of-the-box fully validated EAM platform STATE COLLEGE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant EAM (Enterprise Asset Management) software for life sciences, is pleased to announce the appointment of Jessica Brown as Global Head of Marketing and its newest addition to the executive team. With 20 years of experience in B2B SaaS marketing and a proven track record of driving growth in highly competitive markets, Jessica brings a wealth of expertise to Blue Mountain. In her previous roles, she has successfully developed and executed strategic marketing initiatives that have propelled companies to new heights of success. "On behalf of my entire team, we are overjoyed to welcome Jessica to Blue Mountain," said CEO, David Rode. "Her extensive experience and proven leadership in marketing to highly regulated industries will be instrumental in driving our growth initiatives. T